Lead Product(s): ANG-3777
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: ANG-3777
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Vifor Pharma
Deal Size: $30.0 million Upfront Cash: $30.0 million
Deal Type: Licensing Agreement November 09, 2020
Under the terms of the agreement, Vifor Pharma will receive an exclusive global license, excluding China, Taiwan, Hong Kong and Macau, for all ANG-3777 nephrology indications.
Lead Product(s): StrataGraft skin tissue
Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed
Highest Development Status: Phase III Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2020
U.S. Food and Drug Administration has accepted for review the Stratatech Biologics License Application (BLA) for StrataGraft®, an investigational regenerative skin tissue therapy in development for the treatment of adult patients with deep partial-thickness thermal burns.